BioSpace News Archive

Royal Philips, a global leader in health technology, announced the latest results demonstrating the safety of Philips instant wave-free ratio in the guidance of PCI.

Ocean Biomedical, Inc. announced that its joint venture partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, dosed its first patients in a Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus infection.

Virion Therapeutics, LLC and its Joint Venture partner, Ocean Biomedical, Inc., announced that the first patients have been dosed in the Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus infection.

After surveying the views expressed by 41 advocacy, medical, and transplant-focused organizations on the Uniform Determination of Death Act, a brain injury expert is calling for much-needed reforms to the legal definition of death in the United States.

Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced participation in the following scientific and industry conferences in November.

TELA Bio, Inc. announced that the Company will report third quarter 2023 financial results on Thursday, November 9, 2023.

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the third quarter and provided business updates.

Syndax Pharmaceuticals today announced that it will report its third quarter 2023 financial results and provide a business update on Thursday, November 2, after the close of the U.S. financial markets.

Aptose Biosciences Inc. will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, after the close of the market, and provide a corporate update.

Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2023, which reflect significant pipeline progress and advances in the company’s portfolio renewal strategy.